الفهرس 
Viral HepatitisOnly 14 pages are availabe for public view
 |  | from | 153 |  |  |
| | | from | 153 | | |
Abstract
- 117 -
~!:!!!~~!:>:_L_9!?2S!!:!!!!!?2!!
-a-r-d--R-e-c-o-m-m-e-n-d-a-t-i-o-n-s
This work has been planned and conducted as an analytical
case-control study in which 200 persons from Qalyub a were
screened for HBsAq using reversed passive haemagglu ination
test • Of these # 100 cases were hepatosplenic pati nts with
a presumptive evidence of schistosomiasis , 50 case ’.were
professional blood donors and 50 persons were chose as
normal controls • The~e cases were subjected to his ory taking
and physical examinatjon # urine and stool analysis # intradermal
test for schistosomiasis and HBsAq screening • The
neat conclusions of the present study are ,_
(1) The prevalence rate of HBsAq among normal ,ontrols
was 2% conforming with other studies carried out in different
parts of Egypt •
(2) The prevalence rate of HBSAq among hepatosJ lenic ~
patients was 10% with no statistically significant I Lfference
from controls’ ( p ,>0.05 ) , agreeing with populatiol -based
morbidity s~udies •
(3) The frequency of HBSAq could be statistica: Ly correlated
with decompensated hepatosplenic disease (p.:0.05)
and it was proved that whenever the two conditions f ~e
present together , a rrore advanced hepatocellular ff llure
is anticipated •
(4) Statistical 6nalysis of our results stresSE I tha~
- 118 -
the biological credib5.lity for these correlations ••mLd be
more acceptable if based upon an ”exposure-risk con :ept”
rather than a ”predisuosi tion-risk concept H •
(5) Xn terms of nrevention of severe liver dis ’ase in
Egypt • the advisability of using an effective oral treatment
is more likely to be rewarding medically and econo” .cally
than vaccinating hepatosplenic schistosomal patient I against
hepatitis B •
(6) The ”expecteo attack rate” of pos~-transfu lion
hepatitis B in recipignts of commercial blood in Oa .yubia
is estimated to approximate 3% •
(7) from the point of view of preventive medic .ne • the
exclusion of both commercial and HBsAg-positive ble ’d is the
most reasonable and promising approach •
The present study also recommends the followin I .hI
(1) A large-scale population-based study in wh .ch both
HBsAg and anti-HBs are detected using a sensitive t ,chnique
like radio-immunoassaY (RrA) is necessary to settle the
question of the presumed association between hepati .is Band
schistosomiasis •
(2) A large-scale cohort-study in which SChist ’somal
patients are followed up for the evolution of morbi lity
parametres is required to evaluate the relative rol ,played
by viral hepatitis • :nalnutrition and gastrointesti al haemo-
,’”
- 119 -
rrhaqe in the production of decompensated hepatospl. lie
schistosomiasis •
(3) ~e immunological response of schistosomal lepatosplenic
patients to hepatitis B vaccine has to be s1 Jdied
to evaluate the protection offered by active immuni~ !tion
in these immunoloqically compromised patients •
(4) A comparative cost/effectiveness study of 1 Ie ,~’
suggested measures to reduce the incidence of advanc !d liver
disease in Egypt is needed to ground the choice bet~ ~en
vaccinating hepatosplenic sChistosomal patients agaj 1st
hepatitis B or the large scale application of prazic lantel
therapy for schistoso~iasis •
(5) The risk of post-transfusion hepatitis neec I further
studies to elucidate the most effective risk-reducin
measures •
•